27. Pharm Res. 2018 Apr 17;35(6):118. doi: 10.1007/s11095-018-2400-y.Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer inPreclinical Tumor Models.Schönfeld K(1), Herbener P(1), Zuber C(1), Häder T(1), Bernöster K(2), UherekC(2), Schüttrumpf J(3).Author information: (1)Corporate Research & Development, Biotest AG, Landsteinerstraße 5, 63303,Dreieich, Germany.(2)Corporate Project & Portfolio Management, Biotest AG, Landsteinerstraße 5,63303, Dreieich, Germany.(3)Corporate Research & Development, Biotest AG, Landsteinerstraße 5, 63303,Dreieich, Germany. joerg.schuettrumpf@biotest.com.PURPOSE: Triple-negative breast cancer (TNBC) is related with a poor prognosis aspatients do hardly benefit from approved therapies. CD138 (Syndecan-1) isupregulated on human breast cancers. Indatuximab ravtansine (BT062) is anantibody-drug-conjugate that specifically targets CD138-expressing cells and has previously shown clinical activity in multiple myeloma. Here we show indatuximab ravtansine as a potential mono- and combination therapy for TNBC.METHODS: The effects of indatuximab ravtansine were assessed in vitro in SK-BR-3 and T47D breast cancer cell lines. The in vivo effects of indatuximab ravtansine alone and in combination with docetaxel or paclitaxel were assessed in MAXF401,MAXF1384 and MAXF1322 xenograft TNBC models.RESULTS: CD138+ SK-BR-3 and T47D cells were highly sensitive to indatuximabravtansine. The high CD138-expressing MAXF401 xenograft model demonstrated stronginhibition of tumor growth with 4 mg/kg indatuximab ravtansine. High doses ofindatuximab ravtansine (8 mg/kg), docetaxel and the combination of both led tocomplete remission. In the low CD138-expressing MAXF1384 xenograft model, onlycombination of indatuximab ravtansine and docetaxel demonstrated a significantefficacy. In the MAXF1322 xenograft model, indatuximab ravtansine alone and incombination with paclitaxel elicited complete remission.CONCLUSIONS: These data demonstrate potential use of indatuximab ravtansine incombination with docetaxel or paclitaxel for CD138-positive TNBC.DOI: 10.1007/s11095-018-2400-y PMCID: PMC5904230PMID: 29666962 